Skip Navigation



Annals of Oncology Advance Access published online on October 9, 2006
Annals of Oncology, doi:10.1093/annonc/mdl333
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/1/173    most recent
mdl333v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ahn, S. H.
Right arrow Articles by Yun, Y. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ahn, S. H.
Right arrow Articles by Yun, Y. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology
Received March 16, 2006
Revised June 11, 2006
Accepted August 14, 2006

original article

Health-related quality of life in disease-free survivors of breast cancer with the general population

S. H. Ahn 1 {dagger}, B. W. Park 2 {dagger}, D. Y. Noh 3, S. J. Nam 4, E. S. Lee 5, M. K. Lee 6, S. H. Kim 6, K. M. Lee 6, S. M. Park 6, and Y. H. Yun 6 *

1 Department of Surgery, Asan Medical Center, Seoul, Korea
2 Department of Surgery, Yonsei University Medical Center, Seoul, Korea
3 Department of Surgery, Seoul National University Hospital, Seoul, Korea
4 Department of Surgery, Samsung Medical Center, Seoul, Korea
5 Center for Breast Cancer, National Cancer Center, Goyang, Gyeonggi, Korea
6 Quality of Cancer Care Branch, Research Institute for National Cancer Control and Evaluation, National Cancer Center, Goyang, Gyeonggi, Korea

* To whom correspondence should be addressed.
Y. H. Yun, E-mail: lawyun08{at}ncc.re.kr


  Abstract

Background: Although most of the literature about health-related quality of life (HRQoL) focuses on breast cancer patients, few studies compared the HRQoL in disease-free breast cancer survivors with that of the general population.

Materials and methods: We administered the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and Quality of Life Questionnaire Breast Cancer Module, McGill Quality of Life Questionnaire, Beck Depression Inventory, and Brief Fatigue Inventory to 1933 disease-free survivors for over 1 year after being diagnosed with stage 0 to III breast cancer. We performed multivariate-adjusted analyses in all HRQoL comparisons.

Results: The scores for some HRQoL scales were comparable for both disease-free breast cancer survivors and the general female population; however, there was clinically significant difference in cognitive and social functioning, fatigue, insomnia, and financial difficulties between the two groups. Radiotherapy and systemic adjuvant therapy variables did not limit the HRQoL. Demographic characteristics such as age, time since surgery, and comorbidity were associated with some HRQoL scales and fatigue and depression were associated with almost all HRQoL scales.

Conclusions: Disease-free survivors of breast cancer had good HRQoL, which was less affected by the type of treatment than it was by demographic characteristics, time since surgery, comorbidity, fatigue, and depression.

Keywords: breast cancer; disease-free survivor; health-related quality of life.

{dagger}These authors contributed equally to this work as first authors.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
C. Pitceathly, P. Maguire, I. Fletcher, M. Parle, B. Tomenson, and F. Creed
Can a brief psychological intervention prevent anxiety or depressive disorders in cancer patients? A randomised controlled trial
Ann. Onc., May 1, 2009; 20(5): 928 - 934.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Attard, A. H.M. Reid, T. A. Yap, F. Raynaud, M. Dowsett, S. Settatree, M. Barrett, C. Parker, V. Martins, E. Folkerd, et al.
Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
J. Clin. Oncol., October 1, 2008; 26(28): 4563 - 4571.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Aapro
It is too early to know if intelligence determines cancer incidence and survival
Ann. Onc., January 1, 2007; 18(1): 4 - 5.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.